Dihydrofolate reductase inhibitor / antibiotic
Pregnancy: Avoid in first trimester (folate antagonist — NTD risk); caution in third trimester.
Trimethoprim
Brand names: Trimethoprim, Monotrim
Adult dose
Dose: 200 mg twice daily for 7 days (UTI); Prophylaxis: 100 mg at night
Route: Oral
Frequency: Twice daily (treatment); Once daily at night (prophylaxis)
Max: 400 mg/day
Uncomplicated UTI (women): 200 mg BD for 3–7 days. Prophylaxis (recurrent UTI): 100 mg at night. Pneumocystis prophylaxis (alternative): trimethoprim alone or co-trimoxazole. Avoid in first trimester (antifolate).
Paediatric dose
Dose: 4 mg/kg
Route: Oral
Frequency: Twice daily
Max: 200 mg/dose
Concentration: 50 mg/ml
1 month–5 years: 4 mg/kg (max 200 mg) BD. 6–11 years: 100 mg BD. 12–17 years: 200 mg BD. UTI prophylaxis: 2 mg/kg at night (max 100 mg).
Dose adjustments
Renal
eGFR 15–30: use normal dose for 3 days only; eGFR <15: avoid (if necessary, halve dose with monitoring).
Hepatic
Use with caution in severe hepatic impairment.
Paediatric weight-based calculator
1 month–5 years: 4 mg/kg (max 200 mg) BD. 6–11 years: 100 mg BD. 12–17 years: 200 mg BD. UTI prophylaxis: 2 mg/kg at night (max 100 mg).
Clinical pearls
- First-line for uncomplicated lower UTI in UK (NICE NG112)
- Causes elevation of serum creatinine without changing GFR — check potassium not creatinine trend
- Significant hyperkalaemia risk with ACE inhibitors/ARBs/NSAIDs especially in elderly
- Resistance variable (>20% E. coli resistant in some areas) — use MSU results where possible
- Avoid in first trimester; nitrofurantoin preferred in second trimester
Contraindications
- Blood dyscrasias
- Severe renal impairment
- First trimester of pregnancy (teratogenic — dihydrofolate reductase inhibitor)
Side effects
- GI upset (nausea, vomiting)
- Rash and pruritus
- Hyperkalaemia (especially in renal impairment or with ACE inhibitors/ARBs)
- Megaloblastic anaemia (prolonged use)
- Elevation of serum creatinine (inhibits tubular secretion of creatinine — not true renal impairment)
Interactions
- ACE inhibitors/ARBs — hyperkalaemia risk (trimethoprim has amiloride-like potassium-sparing effect)
- Warfarin — increased anticoagulant effect
- Phenytoin — increased phenytoin levels
- Methotrexate — reduced folate-dependent effects; increased toxicity
- Dofetilide — contraindicated (QT prolongation)
Monitoring
- U&E (potassium — hyperkalaemia risk)
- Renal function
- FBC (prolonged use)
Reference: BNFc; BNF; NICE NG112 UTI; PHE Antimicrobial Prescribing Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023